Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
基本信息
- 批准号:8493984
- 负责人:
- 金额:$ 47.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-07 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:AllelesAntibodiesAntigen PresentationAntigenic VariationAntigensAntiviral AgentsAutoimmune ProcessAutoimmunityB-LymphocytesBindingBypassCatalogingCatalogsCell Culture TechniquesCell DeathCell LineCell surfaceCellsComplexDataDevelopmentEpitopesFlow CytometryFrequenciesGoalsHIVHIV-1HLA AntigensHumanImmuneImmune TargetingImmune responseImmune systemInfectionInfectious AgentMass Spectrum AnalysisMemoryMolecular CloningMonoclonal AntibodiesNaturePatternPeptide FragmentsPeptidesPeripheral Blood Mononuclear CellProteinsProteomeProteomicsPublic HealthReporterReverse Transcriptase Polymerase Chain ReactionSamplingScanningStaining methodStainsSurfaceT cell responseT-Cell Antigen Receptor SpecificityT-Cell ReceptorT-LymphocyteTestingVaccinationViralViral PhysiologyViral ProteinsViremiaVirusVirus Diseasescellular targetingcopingefficacy testingfitnessinnovationnovelresponsesuccesstransmission processvaccination strategy
项目摘要
DESCRIPTION (provided by applicant):
While searching for HIV-1 peptides that distinguish the HLA class I of infected cells, we found that a number of host-derived peptides are unique to HIV-1 infected cells. In aim 1 we propose to discover HLA class I presented host peptides that distinguish HIV-1 infected cells. Using a unique immunoproteomics approach we will catalog targets that HIV-1 cannot antigenically vary. Having discovered host peptide/HLA complexes that distinguish infected cells, we will next pursue the immune targeting of these complexes. A concern in targeting host peptides presented by the HLA of HIV-1 infected cells is autoimmunity; T cell responses (including memory responses) might target host peptides on uninfected cells. In aim 2 we will derive monoclonal antibodies that mimic the T cell receptor's specificity for peptide/HLA complexes (TCR mimics or TCRm antibodies). The goal is to passively administer these TCRm antibodies for the targeting of HIV-1 infected cells. In aim 3 the anti-viral activity of these TCRm antibodies will be tested. In summary, we will apply a proven immunoproteomics approach to identify unrealized HLA presented host peptides that distinguish HIV-1 infected cells. Furthermore, we will target HIV-1 specific host peptides with a new class of antibodies: TCRm. These novel antibodies will be systematically tested for antiviral effects in cell lines, primary human PBMC and against primary HIV-1 isolates. The ultimate goal is to test whether passive administration of TCRm antibodies will impact HIV-1 replication while bypassing the autoimmune consequences of targeting host epitopes.)
Public Health Statement: HIV has been able to elude or defeat immune responses that directly target the virus. We hypothesize that the indirect targeting of HIV infected cells can block transmission of the virus. The goal of this study is to first identify changes unique to the infected cell and to then indirectly attack HIV by targeting infected cells with a new class of antibodies. We intend to target factors that the virus requires rather than the virus itself.
描述(由申请人提供):
在寻找区分感染细胞I类HLA I类的HIV-1肽时,我们发现许多宿主衍生的肽是HIV-1感染细胞独有的。在AIM 1中,我们建议发现HLA I类提出了区分HIV-1感染细胞的宿主肽。使用独特的免疫蛋白质组学方法,我们将分类HIV-1不能抗原变化的靶标。在发现了区分受感染细胞的宿主肽/HLA复合物后,我们接下来将追求这些复合物的免疫靶向。靶向HIV-1感染细胞HLA提出的宿主肽的关注是自身免疫性。 T细胞反应(包括内存反应)可能靶向未感染的细胞上的宿主肽。在AIM 2中,我们将得出模仿T细胞受体对肽/HLA复合物(TCR模拟物或TCRM抗体)的单克隆抗体。目的是被动地施用这些TCRM抗体,以靶向HIV-1感染细胞。在AIM 3中,将测试这些TCRM抗体的抗病毒活性。总而言之,我们将采用一种经过验证的免疫蛋白质组学方法来识别未实现的HLA提出的宿主肽,这些宿主肽可以区分HIV-1感染的细胞。此外,我们将用新的抗体类别靶向HIV-1特异性宿主肽:TCRM。这些新型抗体将在细胞系,原代人PBMC和针对原代HIV-1分离株中系统测试。最终目标是测试被动施用TCRM抗体是否会影响HIV-1复制,同时绕过靶向宿主表位的自身免疫性后果。
公共卫生声明:艾滋病毒已经能够躲避或击败直接针对该病毒的免疫反应。我们假设间接靶向HIV感染细胞可以阻止病毒的传播。这项研究的目的是首先识别受感染细胞独特的变化,然后通过用新的抗体靶向感染细胞来间接攻击HIV。我们打算针对病毒需要的因素,而不是病毒本身。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
- DOI:10.1097/qad.0b013e328355fe8f
- 发表时间:2012-07-17
- 期刊:
- 影响因子:0
- 作者:Norcross MA;Luo S;Lu L;Boyne MT;Gomarteli M;Rennels AD;Woodcock J;Margulies DH;McMurtrey C;Vernon S;Hildebrand WH;Buchli R
- 通讯作者:Buchli R
Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
直接询问 HIV 感染 T 细胞的 I 类 HLA 呈递的病毒肽。
- DOI:10.1128/jvi.01914-14
- 发表时间:2014
- 期刊:
- 影响因子:5.4
- 作者:Yaciuk,JaneC;Skaley,Matthew;Bardet,Wilfried;Schafer,Fredda;Mojsilovic,Danijela;Cate,Steven;Stewart,ChristopherJ;McMurtrey,Curtis;Jackson,KennethW;Buchli,Rico;Olvera,Alex;Cedeño,Samandhy;Plana,Montserrat;Mothe,Beatriz;Brander
- 通讯作者:Brander
Expanding the targets available to therapeutic antibodies via novel disease-specific markers.
- DOI:10.3109/08830185.2011.608136
- 发表时间:2011-10
- 期刊:
- 影响因子:5
- 作者:Weidanz JA;Hildebrand WH
- 通讯作者:Hildebrand WH
TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.
- DOI:10.3109/08830185.2011.604880
- 发表时间:2011-10
- 期刊:
- 影响因子:5
- 作者:Weidanz JA;Hawkins O;Verma B;Hildebrand WH
- 通讯作者:Hildebrand WH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Hildebrand其他文献
William Hildebrand的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Hildebrand', 18)}}的其他基金
rPIV5- and AVLP-vectored vaccine development with public tumor-specific neoantigens
使用公共肿瘤特异性新抗原开发 rPIV5 和 AVLP 载体疫苗
- 批准号:
10831315 - 财政年份:2021
- 资助金额:
$ 47.92万 - 项目类别:
Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
- 批准号:
10404109 - 财政年份:2021
- 资助金额:
$ 47.92万 - 项目类别:
Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
- 批准号:
10630913 - 财政年份:2021
- 资助金额:
$ 47.92万 - 项目类别:
Canine MHC-I genotyping and tumor specific neoantigen determination
犬 MHC-I 基因分型和肿瘤特异性新抗原测定
- 批准号:
10220542 - 财政年份:2021
- 资助金额:
$ 47.92万 - 项目类别:
Human natural killer cell recognition of cytomegalovirus
人类自然杀伤细胞对巨细胞病毒的识别
- 批准号:
8617610 - 财政年份:2014
- 资助金额:
$ 47.92万 - 项目类别:
Direct Discovery of HLA-associated Influenza Epitopes
HLA 相关流感表位的直接发现
- 批准号:
8481492 - 财政年份:2012
- 资助金额:
$ 47.92万 - 项目类别:
Direct Discovery of HLA-associated Influenza Epitopes
HLA 相关流感表位的直接发现
- 批准号:
8434472 - 财政年份:2012
- 资助金额:
$ 47.92万 - 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
- 批准号:
8106378 - 财政年份:2010
- 资助金额:
$ 47.92万 - 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
- 批准号:
7984351 - 财政年份:2010
- 资助金额:
$ 47.92万 - 项目类别:
Discovery and Targeting of HIV-1 Associated Antigens
HIV-1 相关抗原的发现和靶向
- 批准号:
8288353 - 财政年份:2010
- 资助金额:
$ 47.92万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 47.92万 - 项目类别:
The immunogenicity and pathogenicity of HLA-DQ in solid organ transplantation
HLA-DQ在实体器官移植中的免疫原性和致病性
- 批准号:
10658665 - 财政年份:2023
- 资助金额:
$ 47.92万 - 项目类别:
Mapping tumor specific immunopeptidome for antibody-based targeted therapy
绘制肿瘤特异性免疫肽组用于基于抗体的靶向治疗
- 批准号:
10604941 - 财政年份:2023
- 资助金额:
$ 47.92万 - 项目类别:
Novel cell therapy approaches for molecularly defined subsets of therapy-resistant melanoma
针对分子定义的难治性黑色素瘤子集的新型细胞治疗方法
- 批准号:
10780289 - 财政年份:2023
- 资助金额:
$ 47.92万 - 项目类别:
Major Histocompatibility Complex Shapes Early Life Microbial Events to prevent Autoimmunity
主要组织相容性复合体塑造生命早期微生物事件以预防自身免疫
- 批准号:
10731724 - 财政年份:2022
- 资助金额:
$ 47.92万 - 项目类别: